Madlen Jentzsch

37PUBLICATIONS
136CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRegenerative medicine (incl. stem cells)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Nov 05, 2026
Tyrosine kinase inhibitors are associated with reduced AML transformation in systemic mastocytosis with myeloid neoplasm.

|Apr 06, 2026
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma.

Thomas C Wiemers, Michael Rade, Nora Grieb

|Jul 21, 2025
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Julian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch

|Jun 16, 2025
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma.

Patrick Born, David Fandrei, Song Yau Wang

|Mar 12, 2025
Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcome.

Lara Bischof, Jule Ussmann, Uwe Platzbecker

|Jan 15, 2025
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis.

Axel Rüfer, Henning Nilius, Olivier Hermine

Pageof 7

Frequent Collaborators

23 joint publications

Sebastian Schwind

21 joint publications

Vladan Vucinic

15 joint publications

Klaus Metzeler

15 joint publications

Uwe Platzbecker